Sight Sciences, Inc. $SGHT Shares Sold by Bank of America Corp DE

Bank of America Corp DE decreased its stake in shares of Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 63.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 112,256 shares of the company's stock after selling 193,773 shares during the period. Bank of America Corp DE owned about 0.21% of Sight Sciences worth $423,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Sight Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company's stock valued at $6,559,000 after buying an additional 102,609 shares in the last quarter. Americana Partners LLC increased its holdings in shares of Sight Sciences by 12.1% in the 4th quarter. Americana Partners LLC now owns 1,378,980 shares of the company's stock valued at $10,935,000 after acquiring an additional 149,161 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Sight Sciences by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 880,958 shares of the company's stock valued at $6,988,000 after acquiring an additional 27,802 shares in the last quarter. State Street Corp raised its position in shares of Sight Sciences by 11.0% during the 4th quarter. State Street Corp now owns 737,359 shares of the company's stock valued at $5,847,000 after acquiring an additional 73,362 shares in the last quarter. Finally, Integral Health Asset Management LLC bought a new position in Sight Sciences during the fourth quarter worth $3,370,000. 55.51% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SGHT shares. Citigroup reiterated a "neutral" rating on shares of Sight Sciences in a research note on Thursday, August 13th. Weiss Ratings restated a "sell (e+)" rating on shares of Sight Sciences in a research report on Friday, August 7th. Wall Street Zen raised shares of Sight Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, UBS Group boosted their price objective on shares of Sight Sciences from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $7.88.

Sight Sciences Price Performance

Shares of SGHT opened at $8.05 on Thursday. Sight Sciences, Inc. has a 12 month low of $3.19 and a 12 month high of $9.24. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.95 and a quick ratio of 4.67. The stock has a fifty day moving average price of $6.71 and a 200 day moving average price of $5.29. The company has a market cap of $443.47 million, a P/E ratio of -14.38 and a beta of 2.50.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.10. Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%.The company had revenue of $23.39 million for the quarter, compared to analysts' expectations of $21.72 million. On average, research analysts forecast that Sight Sciences, Inc. will post -0.52 earnings per share for the current year.

Insider Activity

In related news, CTO David Badawi sold 7,418 shares of Sight Sciences stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.51, for a total value of $40,873.18. Following the sale, the chief technology officer directly owned 1,982,872 shares in the company, valued at $10,925,624.72. This trade represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Paul Badawi sold 28,684 shares of the business's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total transaction of $155,467.28. Following the transaction, the chief executive officer directly owned 6,122,472 shares of the company's stock, valued at $33,183,798.24. The trade was a 0.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 58,566 shares of company stock worth $318,827 in the last 90 days. 30.40% of the stock is currently owned by insiders.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

Want to see what other hedge funds are holding SGHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sight Sciences, Inc. (NASDAQ:SGHT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.